louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00467467: Alfuzosin Hydrochloride to Relieve Ureteral Stent Discomfort
Official title: Alfuzosin Hydrochloride to Relieve Ureteral Stent Discomfort
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Ureteral Stent Discomfort
Lead sponsor: University of Minnesota
Sponsor class: OTHER
First posted: 2007-04-30
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP

Brief summary: To assess the impact of alfuzosin vs. placebo on ureteral stent discomfort, urinary symptoms and quality of life.


Eligibility criteria: Inclusion Criteria:

* Age \>18
* Undergoing unilateral retrograde ureteroscopy with ureteral stent placement

Exclusion Criteria:

* Significant ureteral trauma
* Concomitant ESWL or other secondary surgical procedure than may impact patient comfort
* Subject with know hypersensitivity to alfuzosin hydrochloride or any component of alfuzosin hydrochloride tablets.
* Pregnancy, nursing mother, or woman of child-bearing age unwilling to take contraception for the duration of the study
* Undergoing bilateral ureteral stenting
* Undergoing antegrade ureteral stenting
* Undergoing simultaneous extracorporeal shockwave lithotripsy
* Urinary infection (fever \>101, positive urine culture, many bacteria on urinalysis)
* Primary bladder dysfunction that would impact ability to void without a catheter
* Neurologic dysfunction that would impair pain sensation
* History of chronic pain or substance abuse
* Potent CYP3A4 inhibitors such as ketoconazole, itraconazole, and ritonavir, since alfuzosin blood levels are increased
* Other alpha-blockers
* Phosphodiesterase type 5 inhibitors for erectile function Any subject for whom the principal investigator feels it would not be in his or her best interest to participate in the study.

Primary outcomes:
measure: effect of study medication on urinary symptoms and quality of life
measure: usage of analgesics/narcotics
Secondary outcomes:
Other outcomes:
Locations:
city: Minneapolis
country: United States
facility: University of Minnesota
state: Minnesota
Study officials:
affiliation: University of Minnesota
name: Manoj Monga, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02938767: Carotid Intima-media Thickness as Cardiovascular Mortality Predictor in Peritoneal Dialysis Patients
Official title: Carotid Intima-media Thickness and Coronary Flow Reserve as Cardiovascular Event and Mortality Predictors in Peritoneal Dialysis Patients: Results of Seven-year Follow-up From a Single Center
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Myocardial Infarction
Keywords: peritoneal dialysis
carotid intima-media thickness
coronary flow reserve
cardiovascular mortality
Lead sponsor: Istanbul University
Sponsor class: OTHER
First posted: 2016-10-19
Enrollment: 57
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients were treated by peritoneal dialysis or followed up as kidney transplant recipient at the Istanbul Medical Faculty from October 1994 to October 2011. Two groups were established for trial as peritoneal dialysis patients and renal transplant recipients. Patients had follow up shorter than six months and missing data not included in the trial

Brief summary: Cardiovascular (CV) disease is the main cause of death in patients on dialysis. The aim of this study is the long-term prognostic values of carotid intima-media thickness and coronary flow reserve in cardiovascular mortality of peritoneal dialysis patients.

Detailed description: Endothelial dysfunction (ED) is a precursor and cause of cardiovascular diseases. Defining of endothelial thickness and coronary microvascular function could be useful for detecting ED. Endothelial dysfunction could be assessed by coronary flow reserve (CFR), carotid intima media thickness (IMT). Repeating measurement of IMT and CFR could be predictor of cardiovascular events and mortality in peritoneal dialysis patients.

Eligibility criteria: Inclusion Criteria:

* Peritoneal dialysis patients whose followed up at least six months from October 1994 to October 2011 (for study group)
* Kidney transplant recipients whose followed up at least six months from October 1994 to October 2011 (for control group)

Exclusion Criteria:

* diabetes mellitus
* valvular heart disease,
* any prior coronary intervention and congestive heart failure
* Patients whose left anterior descending coronary artery (LAD) could not be visualized adequately by Doppler echocardiography were also excluded.

Primary outcomes:
measure: Diseases morbidity
timeFrame: 10-15 years
Secondary outcomes:
measure: Patient Survival
timeFrame: 10-15 years
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine
Study officials:
affiliation: Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine
name: Yasar Caliskan, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02946567: Game to Improve Hearing Health Care Outcomes
Official title: Game to Improve Hearing Health Care Outcomes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Focus of the Study is to Promote Healthy Hearing
Lead sponsor: Photozig, Inc.
Sponsor class: INDUSTRY
Collaborators: name: National Institute on Deafness and Other Communication Disorders (NIDCD)
First posted: 2016-10-27
Enrollment: 159
Sex: ALL
Minimum age (years): 13
Maximum age (years): 20
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The investigators are studying the educational potential of games, with the goal of developing a game to improve learning and promote healthy hearing behaviors.

The project is looking for adolescents and young adults that play games to share their experience and learning from playing games.

The investigators ask participants to fill out an enrollment form/informed consent, complete surveys on healthy hearing habits, and play a game provided by the project.

This projects aims the development and evaluation of a game to educate teenagers and young adults about noise-induced hearing loss, enhance knowledge about hearing, and promote healthy hearing behaviors with the potential to improve hearing health care.


Eligibility criteria: Inclusion Criteria:

* Participants have to be between the ages of 13 and 20 years of age (either gender).
* Participants who are between the ages of 13 and 17 years of age must have a willing and able parent or legal guardian who permits them to participate.
* Participants must have Internet access, an email address (or be able to use parent's/legal guardian's email address), and agree to play a game (random assignment to a group with a different game).

Exclusion Criteria:

* Participants will be excluded if they are cognitively impaired, have any serious medical problem that may interfere with their ability to engage with the online game.
* Those who are not able to read/follow written instructions and individuals with an excessive addiction to games will be excluded.

Primary outcomes:
measure: Knowledge, Attitudes, and Intended Behavior Questionnaire about hearing health care
timeFrame: 9 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Moffett Field
country: United States
facility: Photozig, Inc.
state: California
Study officials:
affiliation: Photozig, Inc.
name: Bruno Kajiyama, MS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01311167: Treatment of Sodium Retention in Liver Cirrhosis With Dexamethasone
Official title: Prospective Randomized Double Blind Placebo Controlled Intervention Study of the Effect of Dexamethasone on the Sodium Retention in Patients With Liver Cirrhosis
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Liver Cirrhosis
Keywords: Dexamethasone
Sodium
Lead sponsor: Insel Gruppe AG, University Hospital Bern
Sponsor class: OTHER
Collaborators: name: University Hospital, Geneva
name: University of Lausanne Hospitals
First posted: 2011-03-09
Enrollment: 2
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Accumulation of salt and water in patients with liver disease (so called liver cirrhosis) is possibly related to the increased effect of steroid hormones on salt reabsorption in the kidney. By reducing overall steroid production with the dexamethasone the accumulation of salt and water could be prevented.


Eligibility criteria: Inclusion Criteria:

* patients with established liver cirrhosis (biopsy or biochemically)
* hepatorenal syndrome type 1 or 2 (with a serum creatinin \>175 umol/l)
* age between 18 and 75
* no bacterial infection
* no cardiovascular or extrahepatic disease (end of life)
* no structural kidney disease
* no hepatocellular carcinoma

Exclusion Criteria:

* age under 15 or over 75
* treatment with corticosteroids (dexamethasone included)
* bacterial infection
* cardiovascular or extrahepatic disease (end of life)
* structural kidney disease (indicated by hematuria, proteinuria)
* hepatocellular carcinoma
* mental disability

Primary outcomes:
measure: Daily sodium excretion of sodium in the urine
timeFrame: 4 days
Secondary outcomes:
measure: Daily potassium excretion
timeFrame: 4 days
measure: weight reduction
timeFrame: 4 days
measure: Reduction of doses of diuretics
timeFrame: 4 days
measure: Reduction of ascites
timeFrame: 4 days
measure: Reduction of cortisol excretion in the urine
timeFrame: 4 days
measure: Reduction of cortisol levels in the urine
timeFrame: 4 days
Other outcomes:
Locations:
city: Lausanne
country: Switzerland
facility: University Hospital Lausanne
state: Vaud
city: Bern
country: Switzerland
facility: University Hospital Inselspital
city: Geneva
country: Switzerland
facility: University Hospital Geneva
Study officials:
References:
Clinical trial NCT01491867: Continuous Intraocular Pressure (IOP) Measurement and Ability to Detect Treatment Effect
Official title: Evaluation of Continuous IOP Measurement and the Influence of Drug Induced IOP Decrease on the Measurement
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Glaucoma
Ocular Hypertension
Keywords: intraocular pressure
Lead sponsor: Semmelweis University
Sponsor class: OTHER
First posted: 2011-12-14
Enrollment: 9
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Continuous intraocular pressure (IOP) measurement with a contact lens sensor may provide more information on the drug-related IOP change than 24-hour IOP measurement with Goldmann applanation tonometry (GAT.

Detailed description: * Participants are washed ot from all glaucoma medication for 6 weeks
* one eye per participant is investigated (study eye)
* 24-h intraocular pressure (IOP) curve is obtained with Goldmann tonometry and Sensimed contact lens sensor tonometry twice, in 14 days
* for Sensimed contact lens curves median values (in arbitrary units), for Goldmann applanation tonometry, mean and SD values are used to characterize the curves, for comparisions % changes are used for the corresponding time periods
* treatment (travoprost 0.005% 1/day) is given to all eyes for 3 months 24-h Goldmann and Sensimed IOP curves are repeated
* IOP curves are determined in arbitrary units and mmHg, respectively, and compared for reproducibility (untreated phase) and relative (%)change (untreated curve vs. under treatment curve) with both methods, respectively

Eligibility criteria: Inclusion Criteria:

* primary open-angle glaucoma (POAG), ocular hypertension(OHT)
* 18 years or older
* C/D \<= 0.7
* no risk for visual field damage
* IOP \> 22 mmHg

Exclusion Criteria:

* Pregnancy and lactation
* Known intolerance to travoprost, topical anesthetic
* Previous ocular surgery at any time
* Previous ocular laser treatment within 1 year

Primary outcomes:
measure: Continuous intraocular pressure (IOP) measurement
timeFrame: 3 months
Secondary outcomes:
measure: Continuous intraocula pressure (IOP) Measurement
timeFrame: 3 months
Other outcomes:
Locations:
city: Budapest
country: Hungary
facility: Departement of Ophthalmology
state: Pest
city: Budapest
country: Hungary
facility: Semmelweis University
Study officials:
affiliation: Semmelweis University
name: Gabor Hollo, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05819567: Effect of a Newly Developed Brace on Foot Biomechanics.
Official title: Effect of a Newly Developed Brace on Foot Biomechanics: An in Vivo Interventional Study With Dynamic Computed Tomography.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Healthy
Keywords: Ankle Brace
Fasciitis, Plantar
Dynamic Computed Tomography
Subtalar Joint Kinematics
Lead sponsor: Vrije Universiteit Brussel
Sponsor class: OTHER
Collaborators: name: Universitair Ziekenhuis Brussel
First posted: 2023-04-19
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: For this interventional study the investigators will recruit a number of healthy volunteers with no symptoms in their lower limbs in the past 6 months and without history of foot and/or ankle conditions and/or surgery. These volunteers will undergo a single Dynamic Computerized Tomography scan session before and after the support is carried, to find out if there is a change in the kinematics of the foot. The results will be analyzed statistically.

Detailed description: For this study the investigators will recruit 15 healthy volunteers who will be undergone a single Dynamic Computed Tomography (4DCT) scanning session before and after wearing a brace, in order to find out if there is a change in foot kinematics. Between the two scans, the subjects will wear the brace and walk for 1 minute. Data collected with the 4DCT will be processed to get 3D imaging of the Subtalar and Midtarsal Joints, needed to quantify the rotations in the three planes of the space (Cardan Angles).

Eligibility criteria: Inclusion Criteria:

* Healthy volunteers;
* 18\<Age\<60;
* No gender restrictions;

Exclusion Criteria:

* Symptoms in their lower limbs in the past 6 months
* History of foot and/or ankle conditions and/or surgery
* Pregnancy

Primary outcomes:
measure: Longitudinal Arch Angle (LAA)
timeFrame: 1 Day
Secondary outcomes:
Other outcomes:
Locations:
city: Brussels
country: Belgium
facility: Vrije Universiteit Brussel
Study officials:
affiliation: Vrije Universiteit Brussel
name: Aldo Scafoglieri, Professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06437067: Study on Prognosis of Acute-on-chronic Liver Failure Complicated by Bacterial or Fungal Infection
Official title: A Real-world Study on the Long-term Prognosis of Acute-on-chronic Liver Failure
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Acute-On-Chronic Liver Failure
Lead sponsor: Tongji Hospital
Sponsor class: OTHER
First posted: 2024-05-31
Enrollment: 400
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Inpatients with ACLF admitted to Tongji Hospital in Wuhan from March 2023 to June 2025.

Brief summary: The subjects of this study were inpatients with ACLF who were admitted to Tongji Hospital in Wuhan from March 2023 to June 2025. After patients were enrolled, The patient's general information (gender, age, past medical history, etc.), complications (ascites, hepatic encephalopathy, hepatorenal syndrome, gastrointestinal bleeding, etc.), laboratory tests (CRP, PCT, INR, WBC, fungal/bacterial diagnostic tests, etc.), symptoms and signs at the time of infection, and at admission (D1), D4, D7, D14, D21, etc.) were recorded Save the blood separately. The patients were divided into fungal infection group, bacterial infection group and non-infection group according to the infection status after admission.


Eligibility criteria: Inclusion Criteria:

1. TBIL ≥ 12 mg/mL and INR ≥ 1.5
2. Chronic hepatitis B

Exclusion Criteria:

(1) \<18 or \>80 years old; (2) primary hepatic or extrahepatic carcinoma; (3) with severe diseases of other organs or systems; (4) pregnancy; (5) imcomplete information

Primary outcomes:
measure: incidence rate of bacterial or fungal infection
timeFrame: 28 days and 90 days
measure: mortality rate of bacterial or fungal infection
timeFrame: 28 days and 90 days
Secondary outcomes:
measure: incidence rate of complications
timeFrame: 28 days and 90 days
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Department of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
state: Hubei
Study officials:
References:
Clinical trial NCT06570967: A Clinical Study of Hyperthyroidism in Children
Official title: A Retrospective and Prospective Observational Study of Hyperthyroidism in Children
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Hyperthyroidism
Lead sponsor: Shengjing Hospital
Sponsor class: OTHER
First posted: 2024-08-26
Enrollment: 1000
Sex: ALL
Minimum age (years): 29
Maximum age (years): 14
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population included male and female with hyperthyroidism aged no more than 14 years. Participants must have not been treated with medication in other hospitals, have no history of autoimmune hepatitis, viral hepatitis, hematological diseases, bone marrow or liver transplantation, and have complete clinical data.

Brief summary: This study intends to conduct a retrospective and prospective study on children with hyperthyroidism, and it is a non-intervention study to collect information on diagnosis and treatment and long-term follow-up of children with hyperthyroidism. To investigate the clinical characteristics, treatment effect, side effects and remission of hyperthyroidism in children, to analyze the predictive factors for the effect of antithyroid drug treatment, remission and recurrence after drug withdrawal, and to explore the risk factors related to the occurrence of antithyroid drug-related adverse reactions.


Eligibility criteria: Inclusion Criteria:

1. Age ≤14 years old
2. Initial diagnosis of hyperthyroidism

Exclusion Criteria:

1. Hyperthyroidism had been treated with medication in other hospitals,
2. History of autoimmune hepatitis, viral hepatitis, hematological diseases, bone marrow or liver transplantation,
3. Patients with incomplete clinical data

Primary outcomes:
measure: Remission of hyperthyroidism in children treated with methimazole. Remission is defined as having clinical and biochemical euthyroidism(FT3, FT4 and TSH are normal) without methimazole treatment for at least 12 months.
timeFrame: 10 years
measure: Adverse effects of methimazole in the treatment of hyperthyroidism in children. Adverse effects are defined as having neutropenia (absolute neutrophil count< 1500/µL), liver dysfunction (AST or ALT> 60 IU/L), rash, arthralgia, myalgia, et al.
timeFrame: 1 year
Secondary outcomes:
measure: Relapse of hyperthyroidism in children treated with methimazole. Relapse was defined as having clinical and biochemical hyperthyroidism (FT3 and FT4 increased and TSH decreased) after discontinuation of methimazole.
timeFrame: 10 years
Other outcomes:
Locations:
city: Shenyang
country: China
facility: Shengjing Hospital of China Medical University
state: Liaoning
Study officials:
References:
Clinical trial NCT02265367: Novel Medication as a Potential Smoking Cessation Aid
Official title: Novel Medication as a Potential Smoking Cessation Aid
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Tobacco Use Disorder
Lead sponsor: University of Minnesota
Sponsor class: OTHER
First posted: 2014-10-15
Enrollment: 56
Sex: ALL
Minimum age (years): 25
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: The purpose of this study is to provide preliminary information assessing if levomilnacipran may be effective at increasing smoking cessation rates.


Eligibility criteria: Inclusion Criteria:

* Be between 25 years old and 55 years old
* Smoke a minimum number of cigarettes per day
* Indicate motivation to quit smoking

Exclusion Criteria:

* Current or history of medical or psychiatric conditions that could interfere with measures being studied or that could be affected by the study medication
* Use of medication that could interfere with measures to be studied or that could be expected to interact with levomilnacipran
* Are pregnant or breast feeding

The investigators will evaluate if there are other reasons why someone may not be eligible to participate

Primary outcomes:
measure: Percent of Days of Confirmed Abstinence (Out of 5 Maximum)
timeFrame: 5 days
Secondary outcomes:
Other outcomes:
Locations:
city: Minneapolis
country: United States
facility: Clinical and Translational Sciences Institute
state: Minnesota
Study officials:
affiliation: University of Minnesota
name: Michael Kotlyar, PharmD
role: PRINCIPAL_INVESTIGATOR
References: